顶级投资人眼中的最佳合作！再鼎医药与MacroGenics 公司喜获“年度最佳合作奖” Read more about 顶级投资人眼中的最佳合作！再鼎医药与MacroGenics 公司喜获“年度最佳合作奖”
引领生物医药创新3.0时代：鼎力创新，合力共筑 “健康中国”——首届CSCO-再鼎肿瘤学高峰论坛在京举行 Read more about 引领生物医药创新3.0时代：鼎力创新，合力共筑 “健康中国”——首届CSCO-再鼎肿瘤学高峰论坛在京举行
再鼎医药宣布马吉妥昔单抗在中国用于治疗复发HER2 阳性转移性乳腺癌患者的新药上市申请获中国国家药品监督管理局受理 Read more about 再鼎医药宣布马吉妥昔单抗在中国用于治疗复发HER2 阳性转移性乳腺癌患者的新药上市申请获中国国家药品监督管理局受理
Zai Lab Announces Upcoming Presentations at January Investor Conferences - SC Read more about Zai Lab Announces Upcoming Presentations at January Investor Conferences - SC
Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases - SC Read more about Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases - SC
Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis - SC Read more about Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis - SC
China NMPA Approves NUZYRA® as a Category 1 Innovative Drug for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI) - SC Read more about China NMPA Approves NUZYRA® as a Category 1 Innovative Drug for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI) - SC